LONDON (Reuters) – European regulators are following in the footsteps of the U.S. Food and Drug Administration with plans to help pharmaceutical companies win approval for novel Alzheimer’s drugs that treat the earliest stages of the memory-robbing disease.
Source: Reuters Medical News